Application of dexmedetomidine nose drop or nasal spray in preparation of sleep aiding medicine
Through the nasal spray form dexmedetomidine, the safety and bioavailability problems of oral and injectable dosage forms are solved, and convenient and efficient sleep aid effects and low side effects are achieved, which is suitable for use in non-hospital environments.
Patent Information
- Application Number
- CN202411065415.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-06-08
- Filing Date
- 2021-06-08
- Publication Date
- 2024-11-15
AI Technical Summary
The existing insomnia drugs are mainly oral preparations, and have safety and side effects. Especially, the dexmedetomidine injection dosage form is prone to side effects when improving sleep time and shortening the incubation period, and is difficult to use in non-hospital environments. The form has low bioavailability and high variability.
Developed a nasal spray of dexmedetomidine, which achieves no-head pass effect and is convenient for drug delivery through nasal delivery. It adopts nasal drops or nasal spray form, combined with appropriate preservatives and thickeners to ensure the stability of the drug. and spray performance, providing lower side effects and higher bioavailability.
It has achieved shortening the sleep latency, prolonging sleep time, reducing side effects, improving the bioavailability and convenience of use of drugs, suitable for self-administration, and safe and effective especially in the absence of hospital facilities.
Smart Images

Figure CN118948739A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical and health care, and particularly relates to a new application of dexmedetomidine in the preparation of sleep-aiding drugs. Background Art
[0002] Insomnia / insomnia is a sleep disorder characterized by frequent and persistent difficulty falling asleep and / or maintaining sleep, which leads to dissatisfaction with sleep and affects the realization of daytime social functions. According to ICSD-3, it can be divided into chronic insomnia, short-term insomnia and other insomnia. According to the cause, it can be divided into primary insomnia and secondary insomnia.
[0003] Market research shows that insomnia drugs in the United States mainly involve zolpidem, eszopiclone, zaleplon, sulvorexant and doxepin, among which zolpidem accounts for more than 80%. Zolpidem is administered in tablet form. At present, the modified sublingual film and spray for its dosage form have not been successful. The modified sustained-release tablets administered orally have achieved a certain degree of success. In China's insomnia drugs, eszopiclone, zopiclone and zolpidem account for three-thirds of the world, and all three drugs are oral tablet preparations. Combined with the above, the current mainstream insomnia drugs are still mainly oral preparations. In terms of medication risks: Zolpidem-type sedatives / hypnotics can lead to physical and mental dependence. The risk of dependence increases with the increase in dose and treatment time. The risk may be higher in patients with a history of mental disorders and / or alcohol or drug dependence; Zopiclone overdose can lead to deep sleep or even coma. Therefore, the sleep aids currently on the market, which are mainly oral preparations, still have risks in terms of medication safety and side effects.
[0004] Dexmedetomidine, (+)-4-[(S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, was jointly developed by Orion Pharma and Abbott. The current marketed dosage form is an injection, and its indications are for sedation during endotracheal intubation and mechanical ventilation of surgical patients undergoing general anesthesia, and for sedation of patients who are intubated and use ventilators during intensive care treatment. On this basis, the industry has further developed dexmedetomidine.
[0005] A prospective experiment disclosed by Oluwaseun Johnson-Akeju (Dexmedetomidine promotes biomimetic non-rapideye movement stage 3 sleep in humans: A pilot study; Oluwaseun Akeju. Clinical Neurophysiology, 201801, 1(129)) showed that the dose of dexmedetomidine injection was positively correlated with the shortened sleep-induced time, and no serious adverse events were observed in healthy subjects. A clinical trial led by Oluwaseun Johnson-Akeju (ClinicalTrials.gov number: NCT02818569) studied the safety and efficacy of oral dexmedetomidine in inducing and maintaining restful sleep. Oluwaseun Johnson-Akeju's study also pointed out that the sleep-promoting effect of dexmedetomidine in this study may have been underestimated because volunteers often complained of irritation at the intravenous injection site all night. This means that for the specific indication of sleep disorders, intravenous injection will cause irritation to the administration site, which is not conducive to the efficacy of the drug. Further exploration is needed to prepare non-invasive, convenient and efficient dexmedetomidine preparations for the treatment of sleep disorders. Unfortunately, this study did not provide experiments or inspiration for other preparations or dosing regimens.
[0006] The PCT international patent application with publication number WO2016061413A1 provides a composition for administering dexmedetomidine through the oral mucosa (sublingually), which can be used to treat sleep disorders, such as insomnia. The results of sublingual animal experiments on rats showed that greater than 40ug / kg significantly prolonged the total sleep time, and 20-40ug / kg significantly reduced the sleep latency (time to fall asleep). However, based on the understanding of neuroanatomy, the sleep center is mainly located in the brainstem, hypothalamus and other parts, and the efficiency of delivering drugs to the site of action through the oral mucosa or sublingually may still be limited. In addition, it is difficult to avoid swallowing through the gastrointestinal tract and the first-pass effect through the oral mucosa or sublingually, which affects the stable effect of the drug.
[0007] Yuan Youhong (Observation on the efficacy of dexmedetomidine on postoperative insomnia; Yuan Youhong. China Practical Medicine, 201608, 11(24)) conducted a study on the effect of 1μg / kg and 0.5μg / kg intravenous infusion of dexmedetomidine on postoperative insomnia. The results showed that intravenous infusion of dexmedetomidine can safely and effectively improve postoperative insomnia. He further mentioned that due to the limitation of intravenous dosage form, there are certain limitations in promotion; if it is made into an oral sustained-release preparation, it can significantly increase patient compliance.
[0008] The above is the recent research progress of dexmedetomidine related to insomnia. It can be seen that: ① At present, dexmedetomidine is still only available as a sedative injection. The new indication for insomnia under this dosage form has confirmed that the dexmedetomidine injection shortens the sleep latency, prolongs the sleep time and is positively correlated with the dose. However, due to the limitations of the characteristics of the injection dosage form, the maximum blood drug concentration of the human body after injection is closely related to the injection dose. Therefore, when developing the injection dosage form, if you want to prolong the sleep time and shorten the sleep latency by increasing the dose, you have to consider the side effects caused by the high blood drug concentration of the high-dose injection. ② The dexmedetomidine injection dosage form is used for insomnia, and it also has the same side effects as when it is used for sedative indications, such as hypotension, bradycardia and dry mouth. ③ Due to the limitations of the injection dosage form itself, it must be administered intravenously by health care professionals, and it is generally difficult to use without hospital facilities and professional skills. ④ Although Yuan Youhong et al. disclosed that it is possible to try to develop it into an oral preparation similar to other common mainstream drug dosage forms for insomnia, due to the high first-pass elimination effect, oral administration of dexmedetomidine via the stomach is likely to have lower systemic bioavailability and greater response variability, and the clinical effect is difficult to predict. In summary, how to overcome the existing defects, develop a dexmedetomidine insomnia drug that is easy to self-administer, and achieve comparable clinical effect expectations and lower side effects is an urgent clinical need. Summary of the invention
[0009] Based on the background introduction, the main treatment drugs for insomnia are mainly oral preparations. Due to its own properties, the clinical effect of dexmedetomidine modified into an oral preparation is difficult to predict. The dexmedetomidine regimen administered sublingually avoids the influence of gastrointestinal elimination effect, but its intervention route is still consistent with the traditional main treatment drugs for insomnia, and there are problems such as limited administration area, limited dosage, and high coefficient of variation in vivo after administration.
[0010] Relying on the platform advantage of the dexmedetomidine nasal spray independently developed by the applicant of the present invention, the present invention further proposes the idea of administering dexmedetomidine through the nose to treat insomnia, and finds that compared with the blank preparation, the dexmedetomidine nasal preparation drug has positive significant differences in shortening the sleep latency, prolonging the sleep time, shortening the drug onset time, and prolonging the duration of continuous action. Even compared with the injection, the dexmedetomidine nasal preparation drug has a comparable or better positive effect in shortening the sleep latency, prolonging the sleep time, shortening the drug onset time, prolonging the duration of continuous action, and lower side effects. Specifically, the nasal spray preparation of the present invention has the advantages of no first-pass effect, easy use, and adaptability to patients with dysphagia. When taking the medicine, 75ug~200ug and above can exert the drug effect, the duration of the drug effect is positively correlated with the shortened sleep time and the dose, and the drug effect (sleep depth) is not positively correlated with the dose, and the minimum effective blood concentration is maintained to play a sleep-aiding effect. This means that although the dosage increases, the depth of sleep is not positively correlated with the dosage, and there is no dose dependence. There is no risk of deep sleep or even coma, and the treatment window is wide, the safety is high, and there is no risk of overdose. In addition, when the nasal spray preparation of the present invention is used as a sleep aid, it can also reduce the side effect of hypotension compared with the injection, and is safer.
[0011] Based on the above findings, the present invention provides the use of dexmedetomidine in the preparation of a drug for treating insomnia, wherein the drug is in a nasal dosage form, and the specific nasal dosage form can be in a variety of specific forms, such as nasal drops, nasal sprays, etc.
[0012] Accordingly, a method for treating insomnia is provided, wherein an effective amount of dexmedetomidine is administered to a subject via the nose. The effective amount of dexmedetomidine is preferably administered via the nose in the form of nasal drops or nasal sprays.
[0013] Accordingly, a drug for treating insomnia is provided, which comprises a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt, solvate or isomer thereof, and is formulated into a dosage form suitable for nasal delivery, preferably a nasal drop or nasal spray preparation for nasal administration.
[0014] Among the above applications, treatment methods, and drugs, the drug for treating insomnia provided by the present invention, according to a specific embodiment of the present invention:
[0015] The insomnia to be treated can be selected from primary insomnia or secondary insomnia. The related manifestations of insomnia may include difficulty falling asleep, sleep maintenance disorder, too short sleep time or fatigue and malaise caused by sleep, decreased concentration and memory, emotional instability, daytime sleepiness or impairment of social life function.
[0016] Insomnia, especially secondary insomnia, is often accompanied by other physiological or psychological factors. Considering the therapeutic effect of insomnia, the drug can also be used in combination with a second therapeutic agent other than dexmedetomidine. The second therapeutic agent can be premixed in the dexmedetomidine drug and co-administered, or it can be administered successively with the dexmedetomidine drug as a separate preparation; the second therapeutic agent can be selected from sedative hypnotic agents or antidepressants, preferably BZDs drugs, NBZDs drugs, melatonin, melatonin receptor agonists, orexin receptor agonists, barbiturates, SSRI drugs, SNRI drugs, NDRI Drugs, SARI drugs, NRI drugs, NaSSA drugs, MAOI drugs, tricyclic drugs, tetracyclic drugs, more preferably estazolam, triazolam, diazepam, alprazolam, lorazepam, clonazepam, zopiclone, eszopiclone, zolpidem, zaleplon, ramirtamide, suvorexan, pentobarbital sodium, trazodone, mirtazapine, fluvoxamine, doxepin, fluoxetine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, duloxetine, bupropion, nefazodone, reboxetine, moclobemide, amitriptyline, clomipramine or mianserin.
[0017] The optional concentration of dexmedetomidine in the drug is 0.001% to 1.3%, preferably 0.0125% to 0.7%, and more preferably 0.006% to 0.108%. Correspondingly, when dexmedetomidine is present as dexmedetomidine hydrochloride, the preferred concentration of dexmedetomidine hydrochloride in the drug is 0.006% to 1.54%, more preferably 0.015% to 0.83%, and more preferably 0.007% to 0.13%. When the drug is a nasal spray preparation, the release amount of dexmedetomidine per press is preferably 2.5 to 650 μg. When the drug is a nasal spray preparation, the spray particle size Dv90 value is preferably 50 to 152.1 μm, more preferably 52 to 142 μm, and further preferably 51 to 66 μm, 66 to 81 μm, 81 to 104 μm or 104 to 152.1 μm. The size of the spray particle size Dv90 value can be controlled by the amount of thickener added. Controlling the Dv90 value of the spray particles helps to obtain a unique drug-time curve suitable for clinical administration for specific purposes.
[0018] Further verification studies have found that in dexmedetomidine drugs, compared with "phenylethanol" or "preservative combination of potassium sorbate and EDTA-2Na", when the preservative is selected as benzalkonium chloride, the stability of dexmedetomidine nasal spray is significantly enhanced. The data show that when the "preservative combination of potassium sorbate and EDTA-2Na" is selected, the total impurities exceed 1% after 10 days of acceleration, and even reach 4.33% in further high temperature experiments, significantly exceeding the controllable level; when "phenylethanol" is selected, after 30 days of high temperature, its API content drops to about 92%, and its total impurity content rises to 1.6%, significantly exceeding the controllable level; and when benzalkonium chloride is selected, no related substances are detected at room temperature for 10 days and accelerated experiments for 30 days. Although related substances (total impurities 0.06%) were detected during the 30-day high temperature process, they are still within a very low range. Further in-depth studies have found that when the carrier is water, the nasal preparation of the present invention has a significantly enhanced prescription stability under specific preservative selection. These specific preservatives are cationic surfactant preservatives such as benzalkonium chloride, benzalkonium bromide or benzethonium bromide, paraben preservatives such as methyl paraben, ethyl paraben, propyl paraben, butyl paraben, isopropyl paraben, isobutyl paraben, propyl paraben sodium or methyl paraben sodium, non-aromatic alcohol preservatives such as propylene glycol or chlorobutanol. Based on the above findings, the preservative of the dexmedetomidine nasal spray of the present invention can be selected as one or a combination of two or more of benzalkonium chloride, benzalkonium bromide, propylene glycol, chlorobutanol, methyl paraben and propyl paraben. When the preservative is selected as benzalkonium chloride or benzalkonium bromide, its concentration can be selected as 0.002% or more, preferably 0.01% or more, more preferably 0.02% or more, and more preferably 0.01% to 0.2%. When the preservative is methyl paraben, its concentration can be selected as 0.01% or more, preferably 0.01% to 0.25%. When the preservative is propyl paraben, its concentration can be selected as 0.01% or more, more preferably 0.02% or more, more preferably 0.02% to 0.075%. When the preservative is propylene glycol, its concentration can be selected as 0.05% or more, preferably 0.05% to 30%, more preferably 0.1% to 10%. When the preservative is chlorobutanol, its concentration can be selected as 0.05% or more, preferably 0.05% to 0.75%. When the preservatives are methyl paraben and propyl paraben, their concentrations can be selected as above 0.01% and above 0.01% respectively, and their concentrations are preferably 0.01%-0.25% and 0.01%-0.075% respectively, and their concentrations are more preferably 0.02%-0.04% and 0.01%-0.02% respectively.When the preservative is selected as propylene glycol and benzalkonium chloride, the concentrations of the two can be selected as 0.1% or more and 0.01% or more, respectively, and the concentrations of the two can be preferably 0.1% to 10% and 0.01% to 0.2% respectively. The type of carrier water can be pharmaceutically acceptable, including but not limited to purified water, water for injection, etc. The single or compound combination of preservatives selected by the present invention can also be used in conjunction with an antioxidant, and the antioxidant can be selected as one or more combinations of EDTA-2Na, BHA tert-butyl hydroxyanisole, BHT2,6-di-tert-butyl-4-methylphenol, sodium pyrosulfite, potassium pyrosulfite, butyl hydroxyanisole, L-ascorbyl palmitate, sodium thiosulfate and vitamin E. In addition, according to the specific embodiment of the present invention, the preservative of the present invention can also be selected as potassium sorbate, but when the preservative is selected as potassium sorbate, EDTA-2Na should not be included in the preparation prescription, and the concentration of potassium sorbate can be selected as 0.01% to 0.2%.
[0019] When the drug is selected as a nasal preparation, especially a nasal spray preparation, different thickeners have different effects on its spray performance. In order to obtain good nasal spray performance, the following thickeners are preferably added, the thickener is a polyvinylpyrrolidone thickener, a cellulose ether thickener, a mucopolysaccharide thickener, and a polyacrylic acid thickener, or a combination of two or more thereof. The polyvinylpyrrolidone thickener can be selected as PVP K30 or PVP K90, the cellulose ether thickener can be selected as a microcrystalline cellulose-sodium carboxymethyl cellulose complex, hydroxypropyl methylcellulose, methylcellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose or hydroxyethyl cellulose, the mucopolysaccharide thickener can be selected as sodium hyaluronate or chondroitin sulfate, and the polyacrylic acid thickener can be selected as carbomer. When the thickener is selected as PVP K30, its concentration can be selected as 0.1% to 5.0%. When the thickener is selected as a microcrystalline cellulose-sodium carboxymethyl cellulose complex, its concentration can be selected as 0.1% to 3.0%. When the thickener is selected as hydroxypropyl methylcellulose, its concentration can be selected as 0.1% to 5.0%, preferably 0.2% to 1.5%. When the thickener is selected as sodium hyaluronate, its concentration can be selected as 0.01% to 1.0%. When the thickener is selected as carbomer, its concentration can be selected as 0.05% to 1.0%. The selected thickener, on the basis of having a certain viscosity enhancement (1.07mPa.s to 8.24mPa.s) to increase the nasal drug retention, can also enable the dexmedetomidine drug to maintain a good spray angle (46.3° to 53.1°) and spray width ([spray width at 3cm, 1.8cm to 2.8cm], [spray width at 6cm, 0.5cm to 3.8cm]), and is non-irritating. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1The effect of the nasal dexmedetomidine hydrochloride preparation on the sleep latency of mice in Experimental Example 2 of the present invention;
[0021] Figure 2 The effect of the nasal dexmedetomidine hydrochloride preparation on the sleep time of mice in Test Example 2 of the present invention;
[0022] Figure 1 and Figure 2 middle:
[0023] Statistics: Mean ± SD, n = 10. DEX: dexmedetomidine hydrochloride; PRO: promethazine; na: nasal administration; iv: injection administration.
[0024] Figure 3 The effect of the nasal dexmedetomidine hydrochloride preparation on the sleep latency of mice in Test Example 3 of the present invention;
[0025] Figure 4 The effect of the nasal dexmedetomidine hydrochloride preparation on the sleep time of mice in Test Example 3 of the present invention;
[0026] Figure 3 and Figure 4 middle:
[0027] Statistics: Mean ± SD, n = 10. DEX: dexmedetomidine hydrochloride; PRO: promethazine; na: nasal administration; iv: injection administration. DETAILED DESCRIPTION
[0028] The present invention will be further explained below in conjunction with the accompanying drawings and specific embodiments.
[0029] Unless otherwise defined herein, technical and scientific terms used are in accordance with common understanding in the industry.
[0030] Herein, in accordance with the usual industry practices, unless otherwise specified, the percentages such as "%" that appear refer to the percentage by weight. In the formulation of the present invention, the density of the prescription solution system is approximately converted to 1 g / mL. For example, with 2.4 mg of dexmedetomidine hydrochloride, water is added to a system of 10 mL, and the concentration of the dexmedetomidine hydrochloride system is 0.24 mg / mL. After the density of the prescription solution system is approximately converted to 1 g / mL, the weight percentage concentration of the dexmedetomidine hydrochloride system is 0.024%; similarly, at this time, based on dexmedetomidine, the converted concentration is 0.2 mg / mL, and the weight percentage concentration is 0.02%.
[0031] In this article, the weight conversion factor between dexmedetomidine hydrochloride and dexmedetomidine is approximately calculated as 1.1822, and the rounding method is followed when converting between them. Unless otherwise stated or constrained by industry practices, the data that need to be calculated in other similar places in this article also follow the rounding method.
[0032] In this article, the specific data values of each listed component may cover a fluctuation of 10% content. For example, "dexmedetomidine concentration 0.02%" may actually cover a concentration range of 0.02% ± 0.002%, that is, 0.018% to 0.022%.
[0033] In this article, unless otherwise stated, the reagents, instruments and other materials used are common commercially available products and can be purchased through regular market purchases.
[0034] Herein, "effective amount" generally refers to the amount of active compounds or agents that can cause biological or medical responses. Biological or medical responses can be at the level of humans, animal individuals, system models, tissues, in vitro cells, etc., which are generally obtained by medical researchers, doctors or clinicians in experiments or clinical studies. "Biological or medical response" can be the recovery, elimination, mitigation or inhibition, or prevention of a disease or symptoms associated with the disease. "Amount" can generally determine the specific amount according to the adaptability of the specific situation of the subject, and a relatively universal range can also be determined for subjects with specific common characteristics. In the present invention, "effective amount" can also preferably refer to the specific amounts described in some specific embodiments or the ranges they jointly support for generalization.
[0035] The terms and abbreviations in the present invention are as follows:
[0036] DEX: abbreviation of dexmedetomidine, i.e. dexmedetomidine
[0037] EDTA-2Na: abbreviation of edetate disodium
[0038] K90: PVP K90, which is polyvinyl pyrrolidone K90, also known as povidone K90, Povidone K90
[0039] K30: PVP K30, which is polyvinyl pyrrolidone K30, also known as povidone K30, Povidone K30
[0040] HEC 250M: the abbreviation of Hydroxyethylmethyl Cellulose 250M, also abbreviated as HEC-M, that is, hydroxyethyl cellulose 250MHEC 250HX: the abbreviation of Hydroxyethylmethyl Cellulose 250HX, also abbreviated as HEC-H, that is, hydroxyethyl cellulose 250HX
[0041] Sodium hyaluronate: SODIUM HYALURONATE
[0042] CL-611: The abbreviation of CL-611, CL-611, trade name, produced by FMC BioPolymer, common name is microcrystalline cellulose-sodium carboxymethyl cellulose complex, also known as Microcrystalline Cellulose and Cellulose Gum
[0043] RL-591: The abbreviation of RL-591, RL-591, trade name, produced by FMC BioPolymer, common name is microcrystalline cellulose-sodium carboxymethyl cellulose complex, also known as Microcrystalline Cellulose and Cellulose Gum
[0044] HPMC E50: abbreviation of hydroxypropyl methylcellulose E50, also known as hydroxypropyl methylcellulose E50, hydroxypropyl methylcellulose E50
[0045] TCB: abbreviation of trichloro-t-butyl alcohol, also known as 2-Trichloromethyl-2-propanol, Chlorobutanol, trichloro-tert-butyl alcohol
[0046] PE: Phenylethyl alcohol, phenyl ethanol
[0047] Methyl ester: abbreviation of methyl paraben, also known as methyl paraben
[0048] Propyl: short for propyl paraben, also known as propylparaben, Propylparaben
[0049] BKB: Benzalkonium bromide
[0050] BKC: Benzalkonium chloride
[0051] CBP: abbreviation of carbopol, i.e. carbomer
[0052] PG: Propylene glycol abbreviation, that is, propylene glycol
[0053] Example:
[0054] This embodiment specifically provides a method for preparing and obtaining a dexmedetomidine nasal spray preparation for treating insomnia, and the general method steps are: weighing API (referring to dexmedetomidine or its pharmaceutically acceptable salt, solvate or isomer thereof) and excipients (excipients include osmotic pressure regulators, preservatives, thickeners and antioxidants, etc., and excipients are selectively added according to the formula), adding an appropriate amount of purified water to dissolve, optionally using a pH regulator to adjust the pH of the system to a predetermined range of 4 to 7, and then adding carrier water to the volume, mixing to obtain a dexmedetomidine nasal preparation. Optionally, the dexmedetomidine nasal spray preparation is further prepared by filling into a borosilicate glass bottle, assembling a metering pump, rolling the cap, and installing a push button.
[0055] In some specific embodiments, examples of different active ingredient concentrations are provided. In the provided dexmedetomidine nasal preparation, dexmedetomidine is in the form of dexmedetomidine hydrochloride, and its concentration, calculated as dexmedetomidine, is 0.006%, 0.02%, 0.0592%, 0.0593%, 0.108%, 0.01%, 0.03%, 0.04%, 0.05%, 0.07%, 0.1%, 0.2%, 0.4%, 0.7%, 1% or 1.3%, respectively.
[0056] In other specific embodiments, several different specifications of dexmedetomidine nasal spray preparations are provided. The nasal spray preparation includes a liquid medicine part and a device part, and the liquid medicine is preloaded in the device. The device includes a metered drug delivery device, which is composed of a metering pump and a container that cooperate with each other. The material of the container is presented in three embodiments of plastic, low borosilicate glass, and medium borosilicate glass, and an actuator is provided on the metering pump. Under the control of the actuator, the drug is delivered by pressing, and then by controlling the dexmedetomidine content concentration of the liquid medicine and the total amount of drug per press, the quantitative delivery of dexmedetomidine is performed at 5μg, 10μg, 15μg, 20μg, 25μg, 30μg, 40μg, 50μg, 60μg, 75μg, 100μg or 125μg per press. When used specifically, single or multiple nasal sprays can be administered.
[0057] In other specific embodiments, the system pH of the nasal preparation is 4 to 7, which can be adjusted by pH adjusters, acidifiers and / or alkalizers, the acidifiers include hydrochloric acid, phosphoric acid, tartaric acid, citric acid, malic acid, fumaric acid and malic acid, and the alkalizers include ammonia water, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, ammonium carbonate and borax; the pH adjuster may further preferably be one or a combination of two or more of hydrochloric acid, phosphoric acid, tartaric acid, citric acid, malic acid, fumaric acid, malic acid, ammonia water, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, ammonium carbonate and borax.
[0058] In other specific embodiments, the osmotic pressure of the nasal preparation can be controlled by the concentration of the osmotic pressure regulator, which is ionic or non-ionic. The ionic osmotic pressure regulator includes boric acid, sodium chloride, calcium chloride, magnesium chloride, zinc chloride or potassium chloride, and the non-ionic osmotic pressure regulator includes anhydrous glucose, monohydrated glucose, dextran, glycerol or D-mannitol; the osmotic pressure regulator is preferably one or a combination of two or more of boric acid, sodium chloride, potassium chloride, anhydrous glucose, monohydrated glucose, dextran, glycerol and D-mannitol, and the osmotic pressure regulator is particularly preferably sodium chloride or potassium chloride, and its concentration is preferably 0.7% to 1%.
[0059] The following is a formula table of several typical examples, in which the pH is adjusted by 1N sodium hydroxide and 1N hydrochloric acid.
[0060]
[0061]
[0062]
[0063] Note [1]: The prescription amount of dexmedetomidine hydrochloride is calculated based on dexmedetomidine. The conversion factor between dexmedetomidine hydrochloride and dexmedetomidine is 1.1822
[0064] Note[2]: “ / ” indicates that such substance is not added to the corresponding prescription.
[0065] Test example
[0066] On the basis of the above-mentioned examples, the dexmedetomidine nasal preparation was experimentally studied with reference to the chapter "Sedatives and Hypnotics" of the pharmacodynamics guidelines for nervous system drugs in the Compilation of Preclinical Research Guidelines for New Drugs (Western Medicines) and other materials.
[0067] Test Example 1: Effect of nasal dexmedetomidine hydrochloride preparation on the spontaneous activity of mice
[0068] 1. Experimental Preparation
[0069] 1.1 Test Agents
[0070] Preparation of test substance, reference substance and solvent:
[0071] Preparation of test sample and solvent: Weigh dexmedetomidine hydrochloride (if present in the formula), sodium chloride and benzalkonium chloride respectively according to the proportions in the table below, add appropriate amount of water to dissolve, adjust the pH to 4.5-5.5, add water to make up to 100%, put into a glass bottle, assemble a metering pump, install a push button, and the test sample and solvent are obtained. The dexmedetomidine hydrochloride nasal spray preparation used as the test sample is sprayed with 50 μL per spray, and each spray contains 10 μg of dexmedetomidine (calculated as free dexmedetomidine). The dexmedetomidine hydrochloride nasal spray preparation (blank preparation) used as the solvent is sprayed with 50 μL per spray, and each spray contains 0 μg of dexmedetomidine (calculated as free dexmedetomidine).
[0072]
[0073] Note: [1] Based on dexmedetomidine.
[0074] [2] Benzalkonium chloride in nC 12 H 25 and nC 14 H 29 The total amount of homologues is calculated on a pure and dry basis.
[0075] [3] “ / ” indicates that the substance is not added.
[0076] Preparation of reference substance 1: Dexmedetomidine hydrochloride injection purchased from the market was used as reference substance 1. Specification of dexmedetomidine hydrochloride injection: 200 μg / 2 mL (calculated as dexmedetomidine).
[0077] Preparation of reference substance 2: Purchase promethazine hydrochloride injection from the market as reference substance 2. Specification of promethazine hydrochloride injection: 50mg / 2mL. Preparation of working solution:
[0078] Preparation of dexmedetomidine hydrochloride nasal preparation working solution: Take an appropriate amount of the test dexmedetomidine hydrochloride nasal spray preparation stock solution, add different volumes of the solvent dexmedetomidine hydrochloride nasal spray preparation (blank preparation) stock solution, and prepare 24, 48, and 96 μg / mL dexmedetomidine hydrochloride nasal preparation working solutions, respectively.
[0079] Preparation of dexmedetomidine hydrochloride injection working solution: Take an appropriate amount of dexmedetomidine hydrochloride injection stock solution and dilute it with sodium chloride injection to make a 1.6 μg / mL dexmedetomidine hydrochloride injection working solution.
[0080] Preparation of promethazine hydrochloride working solution: Take an appropriate amount of promethazine hydrochloride injection stock solution and dilute it with sodium chloride injection to make 0.5 mg / mL promethazine hydrochloride working solution.
[0081] 1.2 Experimental animals
[0082] Mice, ICR strain, SPF grade, 30 males and 30 females. The average weight of male mice is about 30 g, and the average weight of female mice is about 24 g.
[0083] Sixty mice were divided into 6 groups by stratified randomization according to their gender and the number of spontaneous activities (walking distance) before administration, namely, vehicle control group, dexmedetomidine hydrochloride nasal preparation 8 μg / kg group, dexmedetomidine hydrochloride nasal preparation 16 μg / kg group, dexmedetomidine hydrochloride nasal preparation 32 μg / kg group, dexmedetomidine hydrochloride injection 16 μg / kg group, and promethazine 5 mg / kg group.
[0084] 2. Experimental plan
[0085] 2.1 Dosage regimen
[0086]
[0087]
[0088] Note: na: (pipette) nasal drops; iv: (tail vein) injection
[0089] Before administration, each group of mice was placed in an autonomic activity instrument to detect autonomic activity (walking distance and speed) within 10 minutes. Each group of mice was administered according to the above table, and the mice were placed in an autonomic activity instrument immediately after administration. The autonomic activity was detected at 10, 30, 60 and 90 minutes after administration, and the walking distance and speed of the mice within 5 minutes before and after each time point were detected, and compared with the walking distance of each group of mice before administration, and the walking distance inhibition rate and walking speed inhibition rate were calculated.
[0090]
[0091]
[0092] 2.2 Statistics
[0093] The walking distance and speed of mice were recorded using Excel software. SPSS software was used for statistical analysis and regression calculation of the walking distance ED of mice. 50. The walking distance and speed of mice in each dose group were tested for variance homogeneity. If the variance was homogeneous (p>0.05), a one-way ANOVA was performed. If there was a significant difference (p≤0.05), a Dunnett test was performed between each dose group and the control group; otherwise, the test was terminated. If the variance was unequal (p≤0.05), a non-parametric test (Kruskal-Wallis H test, i.e., KW H test) was performed. If the KW H test showed a statistical difference (p≤0.05), a Mann-Whitney U test was performed between each dose group and the control group; otherwise, the test was terminated.
[0094] 3. Test results
[0095] Inhibition rate of dexmemidine hydrochloride nasal preparation on the walking distance of mice (Mean±SD, %)
[0096]
[0097] Note: Compared with the vehicle control group: * p<0.05, ** p<0.01, *** p<0.001; compared with the dexmedetomidine hydrochloride injection 16μg / kg group: # p<0.05, ## p<0.01, ### p<0.001.
[0098] Inhibitory effect of nasal dexmemidine hydrochloride on the walking speed of mice (Mean±SD, %)
[0099]
[0100]
[0101] Note: Compared with the vehicle control group: * p<0.05, ** p<0.01, *** p<0.001; compared with the dexmedetomidine hydrochloride injection 16μg / kg group: # p<0.05, ## p<0.01, ### p<0.001.
[0102] See the above table for statistical results of inhibition rate of walking distance and walking speed of mice.
[0103] The inhibition rates of dexmedetomidine hydrochloride nasal preparations at 8, 16 and 32 μg / kg on the walking distance of mice at 10 and 30 minutes after nasal administration were 4.9%, 15.0%, 74.5% and 14.2%, 23.5%, 69.3%, respectively. The inhibition of locomotor activity was dose-dependent and significantly different from the vehicle control (p<0.01-0.001). 50 The ED value of 24.2 μg / kg for the walking distance of mice was 30 minutes after administration. 50 The inhibition rate of walking distance of mice at 10 and 30 minutes after intravenous administration of dexmedetomidine hydrochloride injection 16 μg / kg was significantly higher than that of dexmedetomidine hydrochloride nasal preparation 8 and 16 μg / kg (p<0.05-0.001), and there was no significant difference with dexmedetomidine hydrochloride nasal preparation 32 μg / kg.
[0104] The inhibition rates of 8, 16 and 32 μg / kg of dexmedetomidine hydrochloride nasal preparation on the walking speed of mice were 71.6%, 74.6%, 92.4% and 74.3%, 77.1% and 90.8% respectively at 10 and 30 minutes after nasal administration, which were dose-dependent and significantly different from the vehicle control (p<0.05-0.001). The inhibition rate of 16 μg / kg of dexmedetomidine hydrochloride injection on the walking speed of mice was significantly higher than that of 8 and 16 μg / kg of dexmedetomidine hydrochloride nasal preparations at 10 and 30 minutes after intravenous administration (p<0.05-0.01), and there was no significant difference with the 32 μg / kg of the nasal preparation. The positive control, promethazine 5 mg / kg, was injected intravenously, and the inhibition rate of the walking speed of mice was 86.4% at 60 minutes after administration, which was significantly different from the vehicle control (P<0.01).
[0105] The inhibitory effect of 32 μg / kg nasal preparation of dexmedetomidine hydrochloride on the spontaneous activity of mice was basically the same as that of 16 μg / kg intravenous injection of dexmedetomidine hydrochloride. Further analysis of the duration of action of the two showed that the inhibition rate of the walking distance of mice at 60 and 90 minutes after nasal administration of 32 μg / kg nasal preparation was 41.1% (p<0.01) and 66.0%, respectively. The inhibition rate of the walking distance of mice at 30 and 60 minutes after intravenous administration of 16 μg / kg injection was 79.5% (p<0.001) and 8.4%, respectively. Therefore, under the same intensity of action, the duration of the effect of nasal preparation of dexmedetomidine hydrochloride was between 60 and 90 minutes, and the duration of the effect of intravenous injection was between 30 and 60 minutes.
[0106] In summary, conclusion:
[0107] Compared with the vehicle control, the intranasal dexmedetomidine hydrochloride inhibited the spontaneous activity of mice in a dose-dependent manner. The onset time of the intranasal dexmedetomidine hydrochloride in mice was within 10 minutes after administration.
[0108] Compared with intravenous administration, nasal administration of 32 μg / kg dexmedetomidine hydrochloride nasal preparation can achieve the same inhibitory effect on the spontaneous activity of mice as that of 16 μg / kg dexmedetomidine hydrochloride injection. Compared with intravenous administration, nasal administration of dexmedetomidine hydrochloride nasal preparation has a longer duration of efficacy.
[0109] Test Example 2: Dexmedetomidine hydrochloride nasal preparation prolongs sodium pentobarbital sleep test
[0110] 1. Experimental Preparation
[0111] 1.1 Test Agents
[0112] Preparation of test substance, reference substance and solvent:
[0113] Preparation of test sample and solvent: Weigh dexmedetomidine hydrochloride (if present in the formula), sodium chloride and benzalkonium chloride respectively according to the proportions in the table below, add appropriate amount of water to dissolve, adjust the pH to 4.5-5.5, add water to make up to 100%, put into a glass bottle, assemble a metering pump, install a push button, and the test sample and solvent are obtained. The dexmedetomidine hydrochloride nasal spray preparation used as the test sample is sprayed with 50 μL per spray, and each spray contains 10 μg of dexmedetomidine (calculated as free dexmedetomidine). The dexmedetomidine hydrochloride nasal spray preparation (blank preparation) used as the solvent is sprayed with 50 μL per spray, and each spray contains 0 μg of dexmedetomidine (calculated as free dexmedetomidine).
[0114]
[0115] Note: [1] Based on dexmedetomidine.
[0116] [2] Benzalkonium chloride in nC 12 H 25 and nC 14 H 29 The total amount of homologues is calculated on a pure and dry basis.
[0117] [3] “ / ” indicates that the substance is not added.
[0118] Preparation of reference substance 1: Dexmedetomidine hydrochloride injection purchased from the market was used as reference substance 1. Specification of dexmedetomidine hydrochloride injection: 200 μg / 2 mL (calculated as dexmedetomidine).
[0119] Preparation of reference substance 2: Purchase promethazine hydrochloride injection from the market as reference substance 2. Specification of promethazine hydrochloride injection: 50mg / 2mL. Preparation of working solution:
[0120] Preparation of dexmedetomidine hydrochloride nasal preparation working solution: take an appropriate amount of dexmedetomidine hydrochloride nasal spray preparation stock solution, add different volumes of dexmedetomidine hydrochloride nasal spray preparation (blank preparation), and prepare 12, 24, and 48 μg / mL dexmedetomidine hydrochloride nasal preparation working solutions, respectively.
[0121] Preparation of dexmedetomidine hydrochloride injection working solution: Take an appropriate amount of dexmedetomidine hydrochloride injection stock solution and dilute it with sodium chloride injection to make 0.8 μg / mL dexmedetomidine hydrochloride injection working solution.
[0122] Preparation of promethazine hydrochloride working solution: Take an appropriate amount of promethazine hydrochloride injection stock solution and dilute it with sodium chloride injection to make 0.5 mg / mL promethazine hydrochloride working solution.
[0123] 1.2 Experimental animals
[0124] Mice, ICR strain, SPF grade, 30 males and 30 females. The average weight of male mice is about 30 g, and the average weight of female mice is about 24 g.
[0125] Sixty mice were divided into 6 groups according to gender and weight by stratified randomization, namely, vehicle control group, dexmedetomidine hydrochloride nasal preparation 4 μg / kg group, dexmedetomidine hydrochloride nasal preparation 8 μg / kg group, dexmedetomidine hydrochloride nasal preparation 16 μg / kg group, dexmedetomidine hydrochloride injection 8 μg / kg group, and promethazine 5 mg / kg group.
[0126] 2. Experimental plan
[0127] 2.1 Dosage regimen
[0128]
[0129]
[0130] Note: na: (pipette) nasal drops; iv: (tail vein) injection
[0131] According to the results of the preliminary test, after intraperitoneal injection of 40 mg / kg sodium pentobarbital in mice, the righting reflex of mice disappeared at about 12.4 minutes. The suprathreshold dose of sodium pentobarbital in mice was set at 40 mg / kg.
[0132] Each group of mice was given different doses of drugs according to the above table. Immediately after administration, a suprathreshold dose of sodium pentobarbital 40 mg / kg (4 mg / mL, 0.1 mL / 10 g body weight) was intraperitoneally injected. The injection time of sodium pentobarbital, the time of disappearance of righting reflex, and the time of recovery of righting reflex were recorded. The disappearance of bilateral righting reflex of mice for 60 seconds was used as the sleep criterion. The sleep latency and sleep time were calculated respectively.
[0133] Sleep latency = time to disappearance of righting reflex - time to sodium pentobarbital injection
[0134] Sleep time = righting reflex recovery time - righting reflex disappearance time
[0135]
[0136] 2.2 Statistics
[0137] The time of sodium pentobarbital injection, the time of righting reflex disappearance, and the time of righting reflex recovery were recorded using Excel software and calculated into sleep latency and sleep time. GraphPad Prism8 software was used for drawing, and SPSS software was used for statistical analysis and regression calculation of mouse sleep latency ED 50 . The sleep latency and sleep time of each dose group were tested for variance homogeneity. If the variance was homogeneous (p>0.05), a one-way analysis of variance was performed. If there was a significant difference (p≤0.05), a Dunnett test was performed between each dose group and the control group; otherwise, the test was terminated. If the variance was unequal (p≤0.05), a non-parametric test (Kruskal-Wallis H test, i.e., KW H test) was performed. If the KW H test showed a statistical difference (p≤0.05), a Mann-Whitney U test was performed between each dose group and the control group; otherwise, the test was terminated.
[0138] 3. Test results
[0139] Effect of intranasal dexmemidine hydrochloride on the hypnotic effect of suprathreshold doses of sodium pentobarbital (Mean±SD)
[0140] Group Sleep latency (min) Sleep time (min) Vehicle control group 12.4±1.3 8.8±5.6 Dexmedetomidine hydrochloride nasal preparation 4 μg / kg group <![CDATA[6.6±2.1 ***## ]]> <![CDATA[23.3±9.0 ***### <!-- 15 -->]]> Dexmedetomidine hydrochloride nasal preparation 8 μg / kg group <![CDATA[4.6±1.3 ***# ]]> <![CDATA[26.4±6.9 ***### ]]> Dexmedetomidine hydrochloride nasal preparation 16 μg / kg group <![CDATA[4.2±0.8 *** ]]> <![CDATA[45.6±17.5 ***# ]]> Dexmedetomidine hydrochloride injection 8 μg / kg group <![CDATA[3.7±1.4 *** ]]> <![CDATA[71.7±19.5 *** ]]> Promethazine 5 mg / kg group <![CDATA[3.1±0.8 *** ]]> <![CDATA[36.4±11.1 *** ]]>
[0141] Statistics: Compared with the vehicle control group, ** p<0.01, *** p<0.001; compared with the dexmedetomidine hydrochloride injection group, # p<0.05, ## p<0.01, ### p<0.001.
[0142] The percentage of inhibition of sleep latency of pentobarbital sodium suprathreshold dose by intranasal dexmemidine hydrochloride (Mean±SD, %)
[0143] Group Sleep latency inhibition rate (%) Vehicle control group / Dexmedetomidine hydrochloride nasal preparation 4 μg / kg group 47.0±17.3 Dexmedetomidine hydrochloride nasal preparation 8 μg / kg group 62.8±10.3 Dexmedetomidine hydrochloride nasal preparation 16 μg / kg group 65.9±6.3 Dexmedetomidine hydrochloride injection 8 μg / kg group 70.3±11.6 Promethazine 5 mg / kg group 75.3±6.7
[0144] See above table and attached Figure 1 and 2 Statistical results of latency and sleep time of mice.
[0145] After intraperitoneal injection of 40mg / kg sodium pentobarbital, the sleep latency of mice was about 12.4min. The intranasal administration of 4, 8, and 16μg / kg of dexmedetomidine hydrochloride preparations shortened the sleep latency of mice in a dose-dependent manner. The inhibition rates of intranasal administration of dexmedetomidine hydrochloride preparations at different doses on the sleep latency of mice were 47.0%, 62.8%, and 65.9%, respectively, which were significantly different from the vehicle control group (p<0.001). Dexmedetomidine hydrochloride intranasal preparations inhibit the sleep latency of mice ED 50 The 95% confidence interval was 4.289 μg / kg, and the 95% confidence interval was 0.741-6.567 μg / kg. The intravenous administration of 8 μg / kg dexmedetomidine hydrochloride injection can also significantly shorten the sleep latency of mice (p<0.001), and its effect is stronger than that of 4 and 8 μg / kg dexmedetomidine nasal preparations (p<0.05-0.01), but it is equivalent to the effect of 16 μg / kg nasal preparations (p>0.05). The positive control promethazine injection 5 mg / kg intravenous injection can also significantly shorten the sleep latency of mice (p<0.001).
[0146] Intraperitoneal injection of 40mg / kg sodium pentobarbital can induce continuous sleep in mice for about 8.8min. Intranasal administration of 4, 8, and 16μg / kg of dexmedetomidine hydrochloride nasal preparations increased the sleep time of mice in a dose-dependent manner, and there were significant differences compared with the vehicle control group (p<0.01-0.001). Intravenous injection of 8μg / kg of dexmedetomidine hydrochloride injection can also significantly increase the sleep time of mice, and its effect is stronger than that of 8 and 16μg / kg of nasal preparations (p<0.05-0.001). The positive control promethazine injection 5mg / kg intravenous injection can also significantly increase the sleep time of mice (p<0.001). Experimental Example 3: Experiment on the effect of nasal dexmedetomidine hydrochloride nasal preparations on the hypnotic effect of subthreshold doses of sodium pentobarbital
[0147] 1. Experimental Preparation
[0148] 1.1 Test Agents
[0149] Preparation of test substance, reference substance and solvent:
[0150] Preparation of test sample and solvent: Weigh dexmedetomidine hydrochloride (if present in the formula), sodium chloride and benzalkonium chloride respectively according to the proportions in the table below, add appropriate amount of water to dissolve, adjust the pH to 4.5-5.5, add water to make up to 100%, put into a glass bottle, assemble a metering pump, install a push button, and the test sample and solvent are obtained. The dexmedetomidine hydrochloride nasal spray preparation used as the test sample is sprayed with 50 μL per spray, and each spray contains 10 μg of dexmedetomidine (calculated as free dexmedetomidine). The dexmedetomidine hydrochloride nasal spray preparation (blank preparation) used as the solvent is sprayed with 50 μL per spray, and each spray contains 0 μg of dexmedetomidine (calculated as free dexmedetomidine).
[0151]
[0152] Note: [1] Based on dexmedetomidine.
[0153] [2] Benzalkonium chloride in nC 12 H 25 and nC 14 H 29 The total amount of homologues is calculated on a pure and dry basis.
[0154] [3] “ / ” indicates that the substance is not added.
[0155] Preparation of reference substance 1: Dexmedetomidine hydrochloride injection purchased from the market was used as reference substance 1. Specification of dexmedetomidine hydrochloride injection: 200 μg / 2 mL (calculated as dexmedetomidine).
[0156] Preparation of reference substance 2: Purchase promethazine hydrochloride injection from the market as reference substance 2. Specification of promethazine hydrochloride injection: 50mg / 2mL. Preparation of working solution:
[0157] Preparation of dexmedetomidine hydrochloride nasal preparation working solution: take an appropriate amount of dexmedetomidine hydrochloride nasal spray preparation stock solution, add different volumes of dexmedetomidine hydrochloride nasal spray preparation (blank preparation), and prepare 24, 48, 96, and 144 μg / mL dexmedetomidine hydrochloride nasal preparation working solutions, respectively.
[0158] Preparation of dexmedetomidine hydrochloride injection working solution: Take an appropriate amount of dexmedetomidine hydrochloride injection stock solution and dilute it with sodium chloride injection to make a 1.6 μg / mL dexmedetomidine hydrochloride injection working solution.
[0159] Preparation of promethazine hydrochloride working solution: Take an appropriate amount of promethazine hydrochloride injection stock solution and dilute it with sodium chloride injection to make a 1.6 mg / mL promethazine hydrochloride working solution.
[0160] 1.2 Experimental animals
[0161] Mice, ICR strain, SPF grade, 35 males and 35 females. The average weight of male mice is about 30g, and the average weight of female mice is about 24g.
[0162] A total of 70 mice were randomly divided into 7 groups according to their sex and weight, including vehicle control group, 8 μg / kg dexmedetomidine hydrochloride nasal preparation group, 16 μg / kg dexmedetomidine hydrochloride nasal preparation group, 32 μg / kg dexmedetomidine hydrochloride nasal preparation group, 48 μg / kg dexmedetomidine hydrochloride nasal preparation group, 16 μg / kg dexmedetomidine hydrochloride injection group, and 16 mg / kg promethazine group.
[0163] 2. Experimental plan
[0164] 2.1 Dosage regimen
[0165]
[0166] Note: na: (pipette) nasal drops; iv: (tail vein) injection
[0167] According to the results of the preliminary test, the subthreshold dose of sodium pentobarbital for mice was set at 35 mg / kg.
[0168] Each group of mice was given different doses of drugs according to the table above. Immediately after administration, a subthreshold dose of sodium pentobarbital 35 mg / kg (3.5 mg / mL, 0.1 mL / 10 g body weight) was intraperitoneally injected. The injection time of sodium pentobarbital, the time of disappearance of righting reflex, the time of recovery of righting reflex, and the number of mice falling asleep within 30 min were recorded. The disappearance of bilateral righting reflex of mice for 60 s was used as the standard for falling asleep. The sleep latency and sleep time were calculated respectively.
[0169] Sleep latency = time to disappearance of righting reflex - time to sodium pentobarbital injection
[0170] Sleep time = righting reflex recovery time - righting reflex disappearance time
[0171] 2.2 Statistics
[0172] The time of sodium pentobarbital injection, time of righting reflex loss, and time of righting reflex recovery were recorded using Excel software and calculated into sleep latency and sleep time. GraphPad Prism8 software was used for drawing, and SPSS software was used for statistical analysis and regression calculation of righting reflex loss ED 50 . The sleep latency and sleep time of each dose group were tested for variance homogeneity. If the variance was homogeneous (p>0.05), a one-way analysis of variance was performed. If there was a significant difference (p≤0.05), a Dunnett test was performed between each dose group and the control group; otherwise, the test was terminated. If the variance was unequal (p≤0.05), a non-parametric test (Kruskal-WallisH test, i.e., KW H test) was performed. If the KW H test showed a statistical difference (p≤0.05), a Mann-Whitney U test was performed between each dose group and the control group; otherwise, the test was terminated.
[0173] 3. Test results
[0174] Effect of intranasal dexmedetomidine hydrochloride on the hypnotic effect of subthreshold doses of sodium pentobarbital (Mean±SD)
[0175] Group Sleep latency (min) Sleep time (min) Vehicle control group 3.9±1.2(n=2) 0.6±1.3(n=10) Dexmedetomidine hydrochloride nasal preparation 8 μg / kg group 5.0±0.9(n=4) <![CDATA[8.3±13.7 ### (n=10)]]> Dexmedetomidine hydrochloride nasal preparation 16 μg / kg group 5.8±0.9(n=4) <![CDATA[14.0±20.7 ### (n=10) <!-- 18 -->]]> Dexmedetomidine hydrochloride nasal preparation 32 μg / kg group 5.6±2.9(n=8) <![CDATA[44.1±33.8 **## (n=10)]]> Dexmedetomidine hydrochloride nasal preparation 48 μg / kg group 6.9±4.2(n=9) <![CDATA[76.1±41.4 *** (n=10)]]> Dexmedetomidine hydrochloride injection 16 μg / kg group 2.7±1.7(n=10) <![CDATA[95.9±25.3 *** (n=10)]]> Promethazine 16 mg / kg group 5.2±3.5(n=10) <![CDATA[38.7±10.4 *** (n=10)]]>
[0176] Note: Animals that did not fall asleep were not included in the sleep latency statistics, and the sleep time of animals that did not fall asleep was recorded as 0 min. Statistics: Compared with the solvent control group, ** p<0.01, *** p<0.001; compared with the dexmedetomidine hydrochloride injection group, ## p<0.01, ### p<0.001.
[0177] See above table and attached Figure 3 and 4 Statistical results of latency and sleep time of mice.
[0178] Intraperitoneal injection of subthreshold dose of sodium pentobarbital induced loss of inversion righting reflex in 2 mice within 30 minutes in the vehicle control group. Each group of mice was given 8, 16, 32, and 48 μg / kg of dexmedetomidine hydrochloride nasal preparation by nasal drops, and the proportion of loss of inversion righting reflex within 30 minutes after subthreshold dose of sodium pentobarbital was 4 / 10, 4 / 10, 8 / 10, and 9 / 10, respectively. In the group of mice injected intravenously with 16 μg / kg dexmedetomidine hydrochloride injection, the proportion of loss of inversion righting reflex within 30 minutes after subthreshold dose of sodium pentobarbital was 10 / 10. The proportion of loss of inversion righting reflex within 30 minutes after 5 mg / kg of promethazine, the positive control, was also 10 / 10. The nasal dexmedetomidine hydrochloride preparation promoted the ED of loss of inversion righting reflex within 30 minutes after subthreshold dose of sodium pentobarbital. 50 The concentration of dexmedetomidine hydrochloride in the nasal preparation of 32 and 48 μg / kg and the injection of 16 μg / kg dexmedetomidine hydrochloride showed the same proportion of mice with loss of righting reflex.
[0179] Mice were given 8, 16, 32, and 48 μg / kg of dexmedetomidine hydrochloride nasal preparations by intranasal drip, and immediately injected with a subthreshold dose of sodium pentobarbital, and the sleep latency was 5 to 7 minutes. The intravenous injection of dexmedetomidine injection 16 μg / kg had a sleep latency of 2.7 minutes. From the analysis of the mean sleep latency, the intravenous injection of dexmedetomidine injection 16 μg / kg had a slightly stronger effect than the various dose groups of dexmedetomidine hydrochloride nasal preparations, but due to the large standard deviation, there was no statistical difference.
[0180] Intraperitoneal injection of subthreshold dose of sodium pentobarbital in the vehicle control group induced loss of righting reflex in only 2 mice within 30 minutes, and the average sleep time was 0.6 minutes. Intranasal injection of 8, 16, 32, and 48 μg / kg of dexmedetomidine hydrochloride nasal preparations and immediate injection of subthreshold dose of sodium pentobarbital increased the sleep time of mice in a dose-dependent manner, and there was a significant difference between the 32 and 48 μg / kg groups of dexmedetomidine hydrochloride nasal preparations and the vehicle control group (p<0.01-0.001). Intravenous injection of 16 μg / kg dexmedetomidine hydrochloride injection also significantly induced an increase in the sleep time of mice (p<0.001), and its effect intensity was significantly stronger than that of 8, 16, and 32 μg / kg of dexmedetomidine hydrochloride nasal preparations (p<0.01-0.001), and was basically consistent with the effect intensity of 48 μg / kg of dexmedetomidine hydrochloride nasal preparations. Compared with the vehicle control, the positive control promethazine 5 mg / kg also significantly increased the sleep time of mice (p<0.001).
[0181] Test example 4:
[0182] Pharmacokinetic study in rats 1
[0183] 1. Formulation and preparation process of nasal spray
[0184] According to the proportions in Table 2.1 below, weigh dexmedetomidine hydrochloride and various excipients respectively, add water to dissolve, adjust the pH to 5.0 with sodium hydroxide, divide into glass bottles, assemble with a metering pump, and add a push button to obtain dexmedetomidine nasal spray.
[0185] Table 2.1
[0186] Name of raw materials Dosage Dexmedetomidine hydrochloride 35.5mg Sodium chloride 1350mg Benzalkonium chloride 30mg Phenylethanol 534.3mg water Up to 150ml
[0187] 2. Animal Testing Process
[0188] The above-mentioned dexmedetomidine nasal spray and commercially available dexmedetomidine hydrochloride injection (2mL: 200μg, Jiangsu Hengrui Medicine Co., Ltd.) were used as test samples, and the prescribed doses of drugs were administered to each group of Sprague Dawley rats (SD rats) via the nose and vein according to Table 2.2. 0.2mL of blood was collected from the jugular vein before and 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours after administration for blood drug concentration detection.
[0189] Table 2.2
[0190]
[0191] Note: The dosage concentration is based on dexmedetomidine, and the injection solution is used after being diluted with normal saline.
[0192] 3. Test results
[0193] The measured blood drug concentrations were analyzed by non-compartmental model using Phoenix WinNonlin (v 6.4). The results are shown in Table 2.3.
[0194] Table 2.3
[0195]
[0196] 4. Results Analysis
[0197] After SD rats were given dexmedetomidine hydrochloride nasal spray via the nose, the absolute bioavailability reached 83.8%, indicating that the dexmedetomidine hydrochloride nasal spray provided by the present invention has very good bioavailability; the peak time (T max ) is only 7.5 minutes, indicating that the nasal spray can be quickly absorbed and take effect quickly. This feature is very beneficial for clinical applications that hope to quickly achieve a sedative effect.
[0198] Rat pharmacokinetic study 2
[0199] 1. Formulation and preparation process of nasal spray
[0200] According to the proportions in Table 2.4 below, weigh dexmedetomidine hydrochloride and various excipients respectively, add water to dissolve, adjust the pH to 5.0 with sodium hydroxide, divide into glass bottles, assemble with a metering pump, and add a push button to obtain dexmedetomidine nasal spray.
[0201] Table 2.4
[0202] Name of raw materials Dosage Dexmedetomidine hydrochloride 0.02% (as dexmedetomidine) Sodium chloride 0.9% Benzalkonium chloride 0.02% water to 100%
[0203] 2. Animal Testing Process
[0204] 1. Blood sample collection, testing and processing
[0205] The above-mentioned dexmedetomidine nasal spray and commercially available dexmedetomidine hydrochloride injection (2mL: 200μg, Jiangsu Hengrui Medicine Co., Ltd.) were used as test samples, and the prescribed doses of drugs were administered to each group of Sprague Dawley rats (SD rats) via the nose and vein according to Table 2.5. 0.2mL of blood was collected from the jugular vein of each group 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours before and after administration, and the blood samples were processed and tested.
[0206] Table 2.5
[0207]
[0208] 2. Gross anatomy and histopathological examination
[0209] Gross anatomy: The rats in the 30 μg / kg nasal spray group were euthanized one day after the seventh administration (i.e., the eighth day of the experiment), and gross anatomy of the main organs (heart, kidney, spleen, liver) and respiratory tract (nasopharynx, bronchi, lungs) of the rats in this group was observed.
[0210] Histopathological examination: The nasopharynx, bronchi, and lungs of all rats in the 30 μg / kg nasal spray group were subjected to histopathological examination.
[0211] 3. Test results
[0212] 1. Pharmacokinetic data results
[0213] The concentration of dexmedetomidine in plasma was determined by a validated LC-MS / MS method and the pharmacokinetic parameters were calculated. The main results are shown in Table 2.6 - Pharmacokinetic parameters (mean) of dexmedetomidine in plasma after a single nasal / intravenous injection in rats:
[0214] Table 2.6
[0215]
[0216] 2. Gross anatomy and histopathological examination
[0217] SD rats were given 30 μg / kg dexmedetomidine hydrochloride nasal spray by intranasal drops for 7 consecutive days. After the end of the administration, gross anatomical observation showed that no abnormal macroscopic changes that may be related to dexmedetomidine hydrochloride nasal spray were found in all rats.
[0218] SD rats were given 30 μg / kg dexmedetomidine hydrochloride nasal spray by intranasal drops for 7 consecutive days. After the administration, histopathological examination showed that no abnormal histopathological changes that may be related to dexmedetomidine hydrochloride nasal spray were found in all rats.
[0219] 4. Results Analysis
[0220] The blood drug concentration of the dexmedetomidine hydrochloride nasal spray of the present invention is slightly lower or substantially equivalent to that of intravenous administration after nasal administration, and the exposure level is also equivalent to that of intravenous administration, the bioavailability is high, the time to peak blood drug concentration is short, and no drug-related toxic reactions are observed after 7 days of administration, which shows that the dexmedetomidine nasal spray of the present invention has good clinical application prospects.
[0221] Test Example 5:
[0222] Clinical efficacy trial of dexmedetomidine nasal spray
[0223] After the subjects were given different doses of the dexmedetomidine nasal spray of the present invention, the subjects' awake and sleeping states were scored and investigated at different times. The scoring grading table is shown in Table 5.1 below, and the scoring results of different investigation time points of each dose group are listed in Table 5.2 below.
[0224] Table 5.1
[0225] Fraction Performance 1 Restlessness 2 Sober, Quiet and Cooperative 3 Lethargy, quick response to instructions 4 Light sleep state, can be quickly awakened 5 Falling asleep and being unresponsive to calls 6 Deep sleep, no response to calls
[0226] Table 5.2
[0227]
[0228]
[0229] The results showed that at a dose of 75-200ug, the nasal spray produced a significant sleep-inducing effect within 30 minutes. As the dose increased, the sleepiness or sleep time shortened, and the duration of the sleep-inducing effect tended to be prolonged. And as the dose increased, there was no significant further increase in the depth of sleep.
[0230] Test Example 6:
[0231] Clinical safety trial of dexmedetomidine nasal spray
[0232] A randomized, double-blind, gender-stratified, two-cycle crossover test design was adopted, with a washout period of 7 days, 6 subjects in each group, and the dexmedetomidine hydrochloride nasal spray of the present invention or one of the commercially available dexmedetomidine hydrochloride injections was administered once on an empty stomach in each cycle. The occurrence of adverse reactions of all subjects was unblinded and counted, and the adverse reaction classification is shown in Table 6.1 below, and the test result statistics are shown in Table 6.2 below.
[0233] Table 6.1
[0234]
[0235] Table 6.2
[0236] Group Number of adverse events of grade 3 or above Relationship with study drug Outcome 25ug injection group 3 (all indicate lower blood pressure) Probably related Recovery 25ug nasal spray group 0 / /
[0237] The results showed that the subjects were randomly assigned to receive the same dose group of dexmedetomidine injection or nasal spray, and the nasal spray showed better safety. The adverse reaction of hypotension caused by the injection observed in this trial was also one of the adverse reactions with a higher frequency (25%) in the product instructions for the injection.
[0238] According to the public safety data of the commercially available dexmedetomidine hydrochloride injection, common adverse reactions of the injection include hypotension, bradycardia and dry mouth; in a clinical trial of 318 patients receiving procedural sedation with injection, the average total dose was 1.6 μg / kg. The incidence of hypotension shown in the safety data of dexmedetomidine hydrochloride injection was compared with the incidence of hypotension (grade 1 adverse reaction event) monitored in the clinical trial of the nasal spray conducted by the applicant, and the results are as follows:
[0239] Adverse Reactions Precedex test group 25μg nasal spray test group 75μg nasal spray test group 125μg nasal spray test group Low blood pressure 54% 25.0% 41.70% 27.30%
[0240] The results show that the incidence of adverse reactions of hypotension in the nasal spray of the present invention is much lower than that of dexmedetomidine hydrochloride injection within the same dosage range. Even if the dosage of the nasal spray of the present invention is further doubled, the incidence of adverse reactions of hypotension is still much lower than that of the existing dexmedetomidine hydrochloride injection, and the incidence of grade 1 adverse reactions of hypotension is less than 50%.
[0241] The present invention is not limited to the above optional implementations, and anyone can derive other various forms of products under the enlightenment of the present invention. The above specific implementations should not be understood as limiting the scope of protection of the present invention. The scope of protection of the present invention should be based on the definition in the claims, and the description can be used to interpret the claims.
Claims
1. Use of dexmedetomidine or a pharmaceutically acceptable salt or solvate thereof in the preparation of a drug for treating insomnia, wherein the drug is in the form of a nasal administration formulation, such as nasal drops or nasal sprays.
2. A drug for treating insomnia, comprising a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt or solvate thereof, which is formulated into a dosage form suitable for nasal delivery, such as nasal drops or nasal spray preparations for nasal administration.
3. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the insomnia is selected from primary insomnia or secondary insomnia.
4. The use or medicine according to claim 3, wherein the symptoms of insomnia include difficulty falling asleep, sleep maintenance disorder, short sleep time or fatigue and malaise caused by sleep, decreased concentration and memory, emotional instability, daytime sleepiness or impairment of social life function.
5. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the drug further comprises a second therapeutic agent in addition to dexmedetomidine, and the second therapeutic agent can be premixed in the dexmedetomidine drug and co-administered, or can be administered successively with the dexmedetomidine drug as a separate preparation; the second therapeutic agent can be selected from sedative hypnotic agents or antidepressant agents, preferably BZDs drugs, NBZDs drugs, melatonin, melatonin receptor agonists, orexin receptor agonists, barbiturates, SSRI drugs, SNRI drugs, NDRI drugs, SARI Drugs, NRI drugs, NaSSA drugs, MAOI drugs, tricyclic drugs, tetracyclic drugs, more preferably estazolam, triazolam, diazepam, alprazolam, lorazepam, clonazepam, zopiclone, eszopiclone, zolpidem, zaleplon, ramirtamide, suvorexan, sodium pentobarbital, trazodone, mirtazapine, fluvoxamine, doxepin, fluoxetine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, duloxetine, bupropion, nefazodone, reboxetine, moclobemide, amitriptyline, clomipramine or mianserin.
6. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the optional concentration of dexmedetomidine in the drug is 0.001% to 1.3%, preferably 0.0125% to 0.7%, more preferably 0.006% to 0.108%, more preferably 0.0012%, 0.0024%, 0.0048%, 0.0096%, 0.0144%, 0.006%, 0.02%, 0.0592%, 0.0 593%, 0.108%, 0.01%, 0.03%, 0.04%, 0.05%, 0.07%, 0.1%, 0.2%, 0.4%, 0.7%, 1% or 1.3%; dexmedetomidine is preferably dexmedetomidine hydrochloride. When it is dexmedetomidine hydrochloride, the preferred concentration of dexmedetomidine hydrochloride in the drug is 0.006% to 1.54%, more preferably 0.015% to 0.83%, more preferably 0.007% to 0.13%.
7. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the drug is a nasal spray preparation, and each press of the nasal spray preparation releases 2.5 to 650 μg of dexmedetomidine, preferably each press releases 5 μg, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 40 μg, 50 μg, 60 μg, 75 μg, 100 μg or 125 μg of dexmedetomidine.
8. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the drug is a nasal spray preparation, and the spray particle size Dv90 value of the nasal spray preparation is 50-152.1 μm, more preferably 52-142 μm, further preferably 51-66 μm, 66-81 μm, 81-104 μm or 104-152.1 μm.
9. The use according to claim 1 or the medicine for treating insomnia according to claim 2, the medicine comprises carrier water and a preservative, the preservative is one or a combination of two or more of a cationic surfactant preservative, a paraben preservative and a non-aromatic alcohol preservative, the cationic surfactant can be selected from benzalkonium chloride, benzalkonium bromide or benzethonium bromide, the paraben preservative can be selected from methyl paraben, ethyl paraben, propyl paraben, butyl paraben, isopropyl paraben, isobutyl paraben, propyl paraben sodium or methyl paraben sodium, the non-aromatic alcohol preservative can be selected from propylene glycol or chlorobutanol; The preservative is further preferably one or a combination of two or more of benzalkonium chloride, benzalkonium bromide, propylene glycol, chlorobutanol, methylparaben and propylparaben; When the preservative is preferably benzalkonium chloride or benzalkonium bromide, the concentration is preferably 0.002% or more, more preferably 0.01% or more, more preferably 0.02% or more, more preferably 0.01% to 0.2%, more preferably 0.002%, 0.005%, 0.0075%, 0.01%, 0.0125%, 0.015%, 0.02%, 0.05%, 0.1% or 0.2%; When the preservative is preferably methyl paraben, its concentration is preferably 0.01% or more, more preferably 0.01% to 0.25%, more preferably 0.01%, 0.02%, 0.04%, 0.05%, 0.1%, 0.15% or 0.25%; when the preservative is preferably propyl paraben, its concentration is preferably 0.01% or more, more preferably 0.02% or more, more preferably 0.02% to 0.075%, more preferably 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06% or 0.07%; When the preservative is preferably propylene glycol, its concentration is preferably 0.05% or more, more preferably 0.05% to 30%, more preferably 0.1% to 10%, more preferably 0.05%, 0.1%, 0.2%, 0.5%, 1%, 5% or 10%; When the preservative is preferably chlorobutanol, its concentration is preferably 0.05% or more, more preferably 0.05% to 0.75%, more preferably 0.05%, 0.1%, 0.2%, 0.3%, 0.5% or 0.75%; When the preservative is preferably methyl paraben and propyl paraben, the concentrations of the two are preferably 0.01% or more and 0.01% or more, respectively. The concentrations of the two are more preferably 0.01% to 0.25% and 0.01% to 0.075%, respectively. The concentrations of the two are more preferably 0.02% to 0.04% and 0.01% to 0.02%, respectively. The concentrations of the two are more preferably 0.04% and 0.02%, respectively. The concentrations of the two are more preferably 0.02% and 0.02%, respectively. The concentrations of the two are more preferably 0.02% and 0.01%; When the preservative is preferably propylene glycol and benzalkonium chloride, the concentrations of the two are preferably 0.1% or more and 0.01% or more, respectively, and the concentrations of the two are more preferably 0.1% to 10% and 0.01% to 0.2%, respectively, and the concentrations of the two are more preferably 0.1% and 0.01%; The preservative may further be potassium sorbate, and the concentration of potassium sorbate is preferably 0.01% to 0.2%, more preferably 0.1%. When potassium sorbate is selected as the preservative, the drug does not contain EDTA-2Na.
10. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the drug further comprises carrier water and a thickener, wherein the thickener is one or a combination of two or more of a polyvidone thickener, a cellulose ether thickener, a mucopolysaccharide thickener and a polyacrylic acid thickener, wherein the povidone thickener may be PVP K30 or PVP K90, the cellulose ether thickener may be microcrystalline cellulose-sodium carboxymethyl cellulose complex, hydroxypropyl methylcellulose, methylcellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose or hydroxyethyl cellulose, the mucopolysaccharide thickener may be sodium hyaluronate or chondroitin sulfate, and the polyacrylic acid thickener may be carbomer; The thickener is further preferably one or a combination of two or more selected from PVP K30, microcrystalline cellulose-sodium carboxymethylcellulose complex, hypromellose, sodium hyaluronate and carbomer; When the thickener is preferably PVP K30, its concentration is preferably 0.1% to 5.0%, more preferably 0.1%, 0.5%, 1%, 3% or 5%; When the thickener is preferably a microcrystalline cellulose-sodium carboxymethyl cellulose complex, its concentration is preferably 0.1% to 3.0%, more preferably 0.1%, 0.2%, 0.5%, 1%, 2% or 3%; When the thickener is preferably hypromellose, its concentration is preferably 0.1% to 5.0%, more preferably 0.2% to 1.5%, more preferably 0.1%, 0.2%, 0.3%, 0.5%, 0.75%, 1.0%, 1.5% or 5.0%; When the thickener is preferably sodium hyaluronate, its concentration is preferably 0.01% to 1.0%, more preferably 0.01%, 0.05%, 0.1%, 0.3%, 0.5% or 1.0%; When the thickener is preferably carbomer, the concentration thereof is preferably 0.05% to 1.0%, more preferably 0.05%, 0.1%, 0.3%, 0.5% or 1.0%.
11. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the drug further comprises an antioxidant, an osmotic pressure regulator and / or a pH regulator; The antioxidant may be selected from one or a combination of two or more of EDTA-2Na, BHA tert-butyl hydroxyanisole, BHT2,6-di-tert-butyl-4-methylphenol, sodium metabisulfite, potassium metabisulfite, butyl hydroxyanisole, L-ascorbyl palmitate, sodium thiosulfate and vitamin E; The osmotic pressure regulator is ionic or non-ionic. The ionic osmotic pressure regulator includes boric acid, sodium chloride, calcium chloride, magnesium chloride, zinc chloride or potassium chloride. The non-ionic osmotic pressure regulator includes anhydrous glucose, glucose monohydrate, dextran, glycerol or D-mannitol. The osmotic pressure regulator is preferably one or a combination of two or more of boric acid, sodium chloride, potassium chloride, anhydrous glucose, glucose monohydrate, dextran, glycerol and D-mannitol. The osmotic pressure regulator is preferably sodium chloride or potassium chloride. When the osmotic pressure regulator is sodium chloride or potassium chloride, its concentration is preferably 0.7% to 1%, more preferably 0.7%, 0.8%, 0.9% or 1.0%; The pH regulator can be selected as an acidifier and / or an alkalizer, the acidifier includes hydrochloric acid, phosphoric acid, tartaric acid, citric acid, malic acid, fumaric acid, lactic acid, ascorbic acid and acetic acid, the alkalizer includes meglumine, trimethylolmethane, sodium phosphate, arginine, lysine, glycine, ammonia water, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, ammonium carbonate and borax; the pH regulator can be further preferably selected from one or a combination of two or more of hydrochloric acid, phosphoric acid, tartaric acid, citric acid, malic acid, fumaric acid, malic acid, ammonia water, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, ammonium carbonate and borax; the pH regulator is more preferably selected from hydrochloric acid and / or sodium hydroxide; The pH of the drug can be selected from 4 to 7, preferably from 5 to 6.5, and more preferably 4, 4.5, 5, 5.5, 6, 6.5 or 7.
12. The use according to claim 1 or the drug for treating insomnia according to claim 2, wherein the prescription composition of the drug is selected from any one of the following tables: Note [1]: The prescription amount of dexmedetomidine hydrochloride is calculated based on dexmedetomidine. The conversion factor between dexmedetomidine hydrochloride and dexmedetomidine is 1.1822; Note[2]: " / " indicates that the substance is not added to the corresponding prescription.
13. Use of dexmedetomidine in the preparation of a drug for treating insomnia with a lower incidence of adverse reactions, wherein the drug is in the form of a nasal administration formulation, such as nasal drops or nasal sprays.
14. The use according to claim 13, wherein the adverse reaction is hypotension, and the lower adverse reaction incidence more preferably refers to an incidence of grade 1 adverse reaction of hypotension being less than 50%.
15. The use according to claim 1 or 13, wherein the drug is a nasal spray preparation, and the single dosage of the nasal spray preparation for the treatment of insomnia is 75-200 μg, 75 μg, 125 μg, 150 μg, 175 μg or 200 μg.
Citation Information
Cited By
Dexmedetomidine microneedle patch as well as preparation method and application thereof
CN119523950A
